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Background. The Pan-American Health Organization has called for reducing (1) human immunodeﬁciency
virus (HIV) mother-to-child transmission (MTCT) to ≤0.30 infections/1000 live births (LB), (2) HIV MTCT risk
to ≤2.0%, and (3) congenital syphilis (CS) incidence to ≤0.50/1000 LB in the Americas by 2015.
Methods. Using published Brazilian data in a mathematical model, we simulated a cohort of pregnant women from
antenatal care (ANC) through birth. We investigated 2 scenarios: “current access” (89.1% receive one ANC syphilis test
and 41.1% receive 2; 81.7% receive one ANCHIV test and 18.9% receive birth testing; if diagnosed, 81.0% are treated for
syphilis and 87.5% are treated for HIV) and “ideal access” (95% of women undergo 2 HIV and syphilis screenings; 95%
receive appropriate treatment). We conducted univariate and multivariate sensitivity analyses on key inputs.
Results. With current access, we projected 2.95 CS cases/1000 LB, 0.29 HIV infections/1000 LB, 7.1% HIV MTCT
risk, and 11.11 intrauterine fetal demises (IUFD)/1000 pregnancies, with signiﬁcant regional variation.With ideal access,
we projected improved outcomes: 1.00 CS cases/1000 LB, 0.10 HIV infections/1000 LB, HIV MTCT risk of 2.4%, and
10.65 IUFD/1000 pregnancies. Increased testing drove the greatest improvements. Even with ideal access, only HIV in-
fections/1000 LB met elimination goals. Achieving all targets required testing and treatment >95% and reductions in
prevalence and incidence of HIV and syphilis.
Conclusions. Increasing access to care and HIV and syphilis antenatal testing will substantially reduce HIV and
syphilis MTCT in Brazil. In addition, regionally tailored interventions reducing syphilis incidence and prevalence
and supporting HIV treatment adherence are necessary to completely meet elimination goals.
Keywords. congenital syphilis; disease elimination; human immunodeﬁciency virus; infectious disease transmis-
sion; mathematical models; vertical transmission.
Mother-to-child transmission (MTCT) of syphilis and
human immunodeﬁciency virus (HIV) remains a sig-
niﬁcant public health concern in Latin America and
the Caribbean (LAC). Despite effective interventions
to prevent vertical transmission, each year an estimated
250 000 children are born in LAC with congenital syph-
ilis (CS) and another 4700 are born with HIV [1, 2]. It
has been shown that investments in preventing MTCT
(PMTCT) of syphilis and HIV are very cost-effective
and will avert morbidity and mortality among children
[3, 4].
In 2013, an estimated 74% of pregnant women in LAC
received HIV testing, with similar syphilis testing rates
[5]. There are many steps along a “cascade” of antenatal
services at which patients are lost from care, including
access to antenatal care (ANC), HIV and syphilis testing
and test result return, access to medications for PMTCT,
infant diagnosis, and retention in treatment [6].
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Among the countries of LAC, Brazil carries a signiﬁcant pro-
portion of the HIV and syphilis burden, yet it also has highly
developed systems of PMTCT services and clinical data col-
lection [7, 8]. The provision of free HIV care since 1996 has
helped to develop HIV and syphilis ANC services [9], which,
coupled with Brazil′s geographical and economic diversity, po-
sitions the country and its regions to serve as a model for many
other LAC countries [10]. Although HIV control has improved
over time, CS remains a substantial problem in Brazil [11, 12].
National ministries of health in the LAC region and the Pan
American Health Organization (PAHO) have declared a goal to
eliminate HIV and syphilis MTCT by 2015, with a plan to in-
tegrate antenatal HIV and syphilis care [13]. In particular, these
goals include the following: reducing MTCT of HIV incidence
to ≤0.30 cases/1000 live births (LB), reducing risk of HIV
MTCT to ≤2.0%, and reducing the incidence of CS to ≤0.50
cases/1000 LB [14].
The operational requirements needed to achieve these goals
are generally understood, but more insight is needed to investi-
gate the impact they may have on PMTCT at the regional and
national level. We expanded a computer simulation model of
PMTCT in HIV [15–17] to include syphilis MTCT, and we pop-
ulated the model with input data speciﬁc to Brazil. We used this
model (1) to project the number of neonatal HIV and syphilis
cases associated with current antenatal services in Brazil and (2)
to project the impact of expanding syphilis- and HIV-related
services in ANC.
METHODS
Analytic Overview
We added syphilis infection and MTCT to a validated computer
model of HIV MTCT [15–17]. The model incorporates each step
of the cascade of ANC, including presentation to care, syphilis
and HIV testing, result return, treatment availability, and treat-
ment adherence (Supplementary Figure 1 and Appendix 1).
We next simulated the cohort of women becoming pregnant
each year in Brazil, and we examined scenarios that represented
both “current” and expanded (or “ideal”) levels of ANC services
(discussed later in the Methods). Our primary outcomes were CS
and pediatric HIV infection rates per 1000 LB, and risk of HIV
MTCT. Because CS is tied closely to intrauterine fetal demise
(IUFD) [18], we also simulated this outcome. To reﬂect a range
of access to care and HIV and syphilis prevalence and incidence
values, we projected outcomes at national and regional levels
within Brazil.
Cohort Characteristics and Treatment Strategies
We simulated a representative cohort of pregnant women, ﬁrst
for the entire country and then separately for Brazil′s 5 admin-
istrative regions (Table 1). Among pregnant women in the na-
tional cohort, the initial syphilis prevalence was 1.0% (ranging
by region from 0.8% to 1.1%) [21], with a syphilis incidence of
0.2% during pregnancy [22] (see Supplementary Appendix 1 for
incidence derivation). The national prevalence of HIV was
0.4%, ranging by region from 0.3% to 0.9% [19]. Among preg-
nant women with chronic HIV infection, 30.2% had CD4
counts ≤350/µL [20]. Human immunodeﬁciency virus MTCT
risks were stratiﬁed by CD4 count and antiretroviral therapy
(ART) receipt, based upon rates in recent literature [35–45].
Pregnant women identiﬁed with syphilis or HIV were eligible
for treatment according to Brazilian and PAHO guidelines [48].
This includes penicillin treatment after syphilis diagnosis and
treatment with 3-drug ART after HIV diagnosis, irrespective
of CD4 count [14, 48]. Treatment and transmission were only
considered until birth; due to rare postnatal syphilis transmis-
sion and wide acceptance of and government funding for for-
mula feeding among HIV-infected Brazilian women, postnatal
transmission and treatment were not considered [49].
Model Structure
The MTCT model is a decision-analytic simulation of a cohort
of pregnant women from conception through delivery (TreeAge
Pro, Williamstown, MA), described in detail in Supplementary
Figure 1 and Appendix 1 [15–17]. The model uses a decision-
tree (deterministic) structure, including probabilities of the fol-
lowing key events in the cascade of antenatal and perinatal care:
presentation to ANC; acceptance of HIV and syphilis testing;
offer of and adherence to ART for PMTCT of HIV; syphilis
treatment (deﬁned as receipt of 1 or more doses of penicillin);
prevalence and incidence of syphilis and HIV; repeat syphilis
testing and treatment; maternal mortality during pregnancy;
HIV testing in labor for women with unknown or negative
HIV status; live birth; infant HIV and syphilis infection by
the time of delivery; and linkage to postnatal care and ART
for mothers (further details in Supplementary Appendix).
Data
We used published Brazilian data to simulate (1) levels of up-
take at each step in the ANC cascade as well as (2) clinical prob-
abilities of HIV and CS transmission, IUFD, maternal HIV
suppression, maternal syphilis cure, and maternal and neonatal
mortality (Table 1). Probabilities of HIV and syphilis MTCT
were based on published literature and were dependent on ma-
ternal status with regard to each disease: for syphilis, early ver-
sus late infection; for HIV, CD4 ≤350/µL versus CD4 >350/µL;
as well as treatment status for both infections. We assumed that
maternal infection with HIV did not affect syphilis transmis-
sion, and syphilis infection did not affect HIV transmission,
given conﬂicting clinical evidence [50–53].
Outcomes
We projected outcomes (1) on the national level for mothers
and (2) both regionally and nationally for newborns. We did
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Table 1. Key Data Parameters Used in a Computer Model of Congenital Syphilis and Mother-to-Child HIV Transmission in Brazil
Parameter Value Range Reference
National Parameters
Maternal Cohort Characteristics
Prevalence of HIV 0.004 0.0032–0.0051 [19]
Proportion of HIV+ with CD4 ≤350/µL 0.302 [20]
Prevalence of maternal syphilis at first ANC visit 0.010 0.008–0.013 [21]
Incidence of maternal syphilis (rate/pregnancy) 0.002 0.001–0.004 [22, 23]
Proportion of maternal syphilis that is early syphilis 0.250 0.100–0.400 [24]
ANC Cascade (Proportions)
Access to ANC (of pregnant women) 0.982 [12]
Test for HIV (of women in ANC) 0.817 0.684–0.928 [19]
Test for HIV in labor (of women delivering at healthcare
facility without prior positive HIV result)
0.189 0.100–0.300 [25]
On antiretroviral regimen (ART) at presentation to ANC
(of diagnosed, HIV-infected women)
0.330 [8]
Start ART if diagnosed as HIV-positive 0.875 0.794–0.936 [19, 26, 27]
Adhere to ART (of all women on ART) 0.735 0.650–0.850 [28, 29]
Test for syphilis at 1st visit (of women in ANC) 0.891 0.795–0.949 [21]
Receive syphilis treatment if positive test (penicillin) 0.810 0.650–0.950 [30]
Deliver at a healthcare facility (of all pregnant
women)
0.990 [12]
Test Characteristics
Sensitivity of HIV test 0.996 [31]
Specificity of HIV test 0.997 [31]
Sensitivity of syphilis test (VDRL) 0.880 0.78–1.00 [32]
Specificity of syphilis test (VDRL) 0.980 [32]
Syphilis probabilities
Maternal syphilis cure after treatment 0.990 [33]
Transmit syphilis to baby
Early syphilis, untreated 0.940 0.750–0.990 [24]
Late syphilis, untreated 0.370 0.190–0.560 [24]
After treatment (any stage) 0.030 0.020–0.070 [34]
HIV probabilitiesa
Transmit HIV to baby
When mother’s CD4 ≤350/µL, no ART 0.207 0.150–0.273 [35–38]
When mother’s CD4 >350/µL, no ART 0.132 0.110–0.175 [35–38]
When mother’s CD4 ≤350/µL, on ART 0.036 0.011–0.036 [39–41]
When mother’s CD4 >350/µL, on ART 0.011 0.004–0.011 [41, 42]
When mother’s CD4 ≤350/µL, AZT in labor only 0.134 0.100–0.300 [40, 43, 44]
When mother’s CD4 >350/µL, AZT in labor only 0.055 0.050–0.080 [43–45]
Mortality of fetus in antenatal period (by maternal
status)
Delivery at a healthcare facility
No HIV or syphilis 0.009 0.007–0.012 [14]b
With HIV, not on ART 0.019 0.009–0.030 [14]c
With HIV, on ART 0.009 [14]
With syphilis, not treated 0.250 0.250–0.438 [18]
With syphilis, treated 0.045 [18, 34]
With syphilis and HIV, on ART 0.250 0.250–0.438 [18]
With syphilis and HIV not on ART 0.260 0.260–0.448 [18]
Delivery at home (additional risk) 0.010 0.000–0.020 Assumption
Mortality of mother from ANC period to 6 wks post
delivery
0.0006 [14]
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not examine maternal outcomes at the regional level due to a
desire to maintain focus on infant transmission and their out-
comes. Modeled neonatal outcomes included the expected
number of neonatal HIV and CS cases/1000 LB among the ge-
neral population as well as cases of IUFD/1000 pregnancies and
the HIV MTCT risk (deﬁned as the proportion of HIV-infected
women transmitting HIV to their infants during pregnancy or
delivery). The absolute number of neonatal HIV and syphilis
cases in each region were estimated by multiplying the projected
HIV and syphilis cases/1000 LB by the number of births nation-
ally, as well as in each region [12, 54]. All national-level projec-
tions were based on aggregate national data (Table 1), whereas
regional-level analyses used data collected within each region
(Table 2). Modeled maternal outcomes included the proportion
of syphilis-infected women achieving syphilis cure and the pro-
portion of HIV-infected women receiving and adhering to ART
until delivery.
Scenarios
We compared a “current access” scenario using the best avail-
able estimates of current access to PMTCT services (Table 1) to
an “ideal access” scenario (95% of women in ANC tested for
HIV and syphilis; 95% treated with positive result). In cases
where ideal access was insufﬁcient to meet elimination goals
for the LAC region, we modeled (1) further expansion of
PMTCT services as well as (2) changes in HIV and syphilis
Table 1 continued.
Parameters varied by region National North Northeast Southeast South Midwest References
Regional Parameters
Maternal HIV prevalence 0.004 0.004 0.003 0.003 0.009 0.003 [19]
Maternal syphilis prevalence 0.010 0.008 0.011 0.010 0.011 0.010 [21]
Test for HIV in ANC 0.817 0.699 0.684 0.882 0.928 0.832 [19]
Test for HIV in labor 0.189 0.169 0.285 0.162 0.095 0.141 [25]
Start antiretroviral regimen if HIV-positive 0.875 0.794 0.800 0.942 0.904 0.817 [7, 8, 26, 27, 46,
47]
Test for syphilis at 1st ANC visit 0.891 0.795 0.848 0.918 0.949 0.861 [21]
Test for syphilis on return visit 0.411 0.292 0.310 0.445 0.567 0.428 [21]
Abbreviations: ANC, antenatal care; ART, antiretroviral treatment; AZT, zidovudine; HIV, human immunodeficiency virus; VDRL, Venereal Disease Research
Laboratory.
a Assumes reduced transmission given higher cesarean-section prevalence (Supplementary Appendix 1).
b Subtracting mortality from HIV, syphilis, and home delivery.
c Assumption of 0.010 increased mortality with untreated HIV.
Table 2. Projected Outcomes in a Model-Based Study of HIV and Syphilis PMTCT in Brazil
Infant Outcomesa
“Current
Access”
Test 95% of
Women in ANC
Treat 95% of Women Diagnosed
With HIV and Syphilis
Both Test and Treat 95%:
“Ideal Access”b
Cases per 1000 Live Births
Congenital syphilisc 2.95 1.51 2.42 1.00
HIV 0.29 0.14 0.20 0.10
IUFD 11.10 10.80 10.90 10.70
% Transmission
HIV MTCT 7.1% 3.4% 4.8% 2.4%
Maternal Outcomes At Birth, Current Access At Birth, Ideal Accessb % Change With Scale-up
Maternal syphilis prevalence 0.3% 0.1% −75.2%
% HIV+ mothers on ART and in care 51.7% 83.6% +61.7%
Abbreviations: ANC, antenatal care; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IUFD, intrauterine fetal demise; MTCT, mother-to-child
transmission; PAHO, Pan American Health Organization; PMTCT, preventing MTCT.
a PAHO elimination targets are reducing HIVMTCT to ≤0.3 cases/1000 live births (LB), reducing HIV MTCT risk to ≤2.0%, and reducing syphilis MTCT to ≤0.50/1000
LB by 2015.
b
“Ideal” access: 95% of women in ANC are tested for HIV and syphilis, 95% of women diagnosed with either condition are treated.
c Congenital syphilis is clinically defined as the sum of live-born infants with clinical evidence of syphilis infection and cases of IUFDs attributable to syphilis
(Supplementary Appendix 1).
4 • OFID • Cerda et al
incidence and prevalence, to identify conditions necessary to
meet elimination goals.
Model Validation and Sensitivity Analyses
In previous work, we validated model-derived outcomes of HIV
MTCT risk against published data [15–17]. For this analysis, we
also validated the expanded model for syphilis transmission
outcomes, both nationally and in selected published regions
of Brazil (Supplementary Appendix 1).
We conducted sensitivity analyses on key clinical and access-
to-care parameters related toHIV and syphilis (ranges in Table 1).
These included one-way and multiway sensitivity analyses in
which we varied HIV and syphilis test sensitivity and speciﬁcity,
testing rates, treatment rates, prevalence of HIV, and prevalence
and incidence of syphilis (incorporating the impact of sexual be-
havior as well as test characteristics; Supplementary Appendix).
Values for sensitivity analyses were chosen based on ranges of
published data. Results of sensitivity analyses were shown (1) if
they led to >10% change in an output parameter or (2) where
they were anticipated to inform decisions in prioritizing PMTCT
interventions despite having a <10% impact. For parameters
that are well established in literature or judged to have limited
implications on policy, base case parameters were not varied
(ranges omitted in Table 1). The incidence of HIV during preg-
nancy was not included in the model because it had minimal
impact over a reasonable range consistent with a prevalence of
0.4% and lifelong disease duration. We also varied the effective-
ness of penicillin in preventing CS and of ART in preventing HIV
MTCT; higher effectiveness serves as a proxy measure for earlier
testing, earlier treatment, higher medication availability, and
greater medication adherence.
RESULTS
Current Access to Care
Infant Outcomes
At the national level for Brazil, using current access, CS and
neonatal HIV rates were projected to be 2.95 and 0.29 cases/
1000 LB, respectively (Table 2), with 11.11 IUFD/1000 LB.
This meets the PAHO goals for cases of HIV/1000 LB, but it
does not reach the other 2 HIV and CS goals. Among pregnant
women with HIV, the projected HIV MTCT risk was 7.1%
(Table 2, Figure 1, Current access). These results were consistent
with published ﬁgures, with the exception of syphilis, which we
projected to be slightly lower than the 3.3 cases/1000 LB esti-
mated by the Brazilian Ministry of Health (MOH) [11]. Al-
though we deﬁned an incident case clinically, Brazilian MOH
estimates deﬁne a case as any exposure without appropriate
treatment (Supplementary Appendix). Projected infant out-
comes varied widely between the 5 administrative regions of
Figure 1. Mother-to-child transmission (MTCT) risk among human immunodeﬁciency virus (HIV)-positive women. The vertical axis shows the risk of HIV
transmission from mother to child, with the horizontal axis demonstrating each modeled scenario. The MTCT risk is not below 2.0% for the “current access,”
the condition where 95% of mothers are tested, the condition where 95% of mothers are treated, or even for the “ideal access” scenario (95% test and 95%
treat). The MTCT risk among HIV-positive women is below 2.0% only under ideal access with lowest assumed transmission risk. Abbreviation: PAHO, Pan
American Health Organization.
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Brazil (Figure 2). Congenital syphilis occurred with greatest fre-
quency in the North (2.99 cases/1000 LB) and Northeastern
(3.43 cases/1000 LB) regions. Cases of neonatal HIV and HIV
MTCT rates varied according to HIV prevalence and PMTCT
uptake: the South region had the highest rates of projected neo-
natal HIV cases, with 0.56 cases/1000 LB, but the North and
Northeastern regions had the highest projected MTCT risks,
at 8.5% and 7.9%, respectively.
Figure 2. Birth outcomes by region. (A) Projected mother-to-child transmission (MTCT) of syphilis per 1000 live births (LB) is highest in the Northeast
region, which together with the Southeast makes up over 70% of all neonatal syphilis cases in Brazil. The “ideal access” scenario signiﬁcantly reduces
syphilis MTCT in all regions of the country, with 4110 syphilis cases avoided in the Northeast and Southeast alone. (B) Human immunodeﬁciency virus (HIV)
cases/1000 LB are highest in the South and North, but by absolute number of cases the highest rates of pediatric HIV cases are seen in the South and
Southeast. The South and Southeast alone account for over 50% of all pediatric HIV cases. Ideal access could result in a reduction of 250 pediatric HIV
cases each year. (C) The risk of MTCT among HIV-infected mothers is highest in the North and Northeast region of Brazil. Achieving ideal access uptake will
result in 2.4% risk of MTCT across each region. This represents a signiﬁcant risk reduction in even the South and Southeast, which have the lowest MTCT
risk. Abbreviations: CA, current access; IA, ideal access; PAHO, Pan American Health Organization.
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Maternal Outcomes
In the current access analysis at the national level, maternal
syphilis prevalence was 0.3% at the time of delivery (Table 2).
The percentage of HIV-infected women on ART and in care
was 51.7% at delivery.
Ideal Access to Care
Infant Outcomes
At the national level, the rates of neonatal HIV and CS in the
ideal access scenario were substantially lower than in the current
access scenario, driven largely by improvements in maternal
testing for HIV and syphilis. Achievement of ideal access was
projected to reduce CS to 1.00 cases/1000 LB and neonatal
HIV to 0.10 cases/1000 LB, with 10.7 IUFD/1000 LB and a pro-
jected MTCT risk of 2.4% (Table 2; Figure 1). These results con-
tinue to meet PAHO goals for HIV cases/1000 LB (already met
in the current access scenario) and approach the PAHO goals
for HIV MTCT risk, but a signiﬁcant gap remains for CS.
The impact of current and ideal access on infant outcomes at the
regional level is shown in Figure 2. At current access, PAHO goals
were met only for cases of HIV/1000 LB, and only in the Northeast
and Midwest regions (both with rates of 0.23 cases/1000 LB) and
the Southeast region (0.21 cases/1000 LB). Achieving ideal access
was projected to meet PAHO elimination targets for number of
cases of neonatal HIV/1000 LB in all regions, but even ideal access
conditions would not reach elimination targets for cases of CS/
1000 LB or for HIV MTCT risk in any of the regions.
Maternal Outcomes
Achieving ideal access was also projected to improve postpar-
tum maternal outcomes at birth (Table 2). Among postpartum
women, syphilis prevalence at birth decreased from 0.3% in the
current access scenario to 0.1% with ideal access, and the pro-
portion of HIV-infected women on ART and in care at birth
increased from 51.7% in the current access scenario to 83.6%
in the ideal access scenario.
Sensitivity Analyses
In all one-way sensitivity analyses in which single parameters
were varied through the ranges shown in Table 1, elimination
targets for cases of CS/1000 LB and HIV MTCT were not met
(Supplementary Figures S2 and S3). Simultaneous variations in
multiple parameters were required to meet elimination targets.
For example, HIV MTCT was ≤2.0% only when assuming both
ideal access and the lowest published HIV transmission risks
(Table 1), reaching rates as low as 1.3% under these conditions
(Figure 1). When we examined the individual contributions
of the 2 key improvements of ideal access, we found that improve-
ments in testing (with no change in the proportion of tested
women who were then treated) had a greater impact on both
CS and HIV outcomes than improvements in treatment of
those tested at the current access testing rate (Figure 1; Table 2).
The number of cases of CS was highly sensitive to maternal
syphilis prevalence and incidence. The CS goal was only reached
in the current access scenario when maternal syphilis incidence
was set at zero andmaternal syphilis prevalencewas 0.3%; this led
to a CS rate of 0.48 cases/1000 LB (Figure 3). When maternal
syphilis incidence was assumed to be 0.1%, it was not possible
to reach elimination goals with current access. Even with ideal
access and maternal syphilis incidence of zero, a syphilis preva-
lence of ≤0.5% was needed to reach PAHO goals. The base-case
maternal syphilis incidence of 0.2% required a prevalence of
<0.2% to reach the regional goals at ideal access. If we simultane-
ously assumed ideal access, improved syphilis test sensitivity
(99.0%), greater efﬁcacy of syphilis treatment on transmission
risk (1.0% syphilis transmission risk after treatment, compared
with 3.0% in the base case), and a lower maternal syphilis inci-
dence of 0.1%, projected syphilis “elimination”was possible at the
current syphilis prevalence (projected CS rate 0.36 cases/1000
LB). Figures 1–3 and the Supplementary Appendix report addi-
tional sensitivity analyses; all other sensitivity analyses for which
ranges are shown in Table 1 did not have a substantial effect on
model results.
DISCUSSION
We used a validated computer model to examine the feasibility
of achieving elimination targets for neonatal HIV and CS in
Brazil and generated 4 key ﬁndings. First, we found that the cur-
rent levels of ANC uptake in Brazil lead to HIV and syphilis
transmission risks that do not yet meet most regional elimina-
tion goals. Increases in maternal testing would lead to the great-
est improvements in transmission rates for both HIV and
syphilis, and achievement of ideal testing and treatment levels
together would have a signiﬁcant impact on both diseases (Fig-
ure 1; Table 2). However, improved testing and treatment in iso-
lation will be insufﬁcient to completely achieve the elimination
targets for either disease. This is particularly a challenge for
syphilis elimination: current syphilis prevalence levels and inci-
dence rates during pregnancy, together with imperfect test sen-
sitivity, attenuate the effects of increasing access to ANC.
Second, to build upon this ﬁnding, we simulated the condi-
tions necessary to achieve CS elimination goals. With the 2015
deadline now upon us, cases of CS (projected at 2.95/1000 LB)
are still far from the target of ≤0.50/1000 LB. Our results show
that elimination of syphilis could be reached with a combination
of increased access to testing and treatment services, together
with improvements in syphilis test sensitivity, reduction of ma-
ternal syphilis prevalence, and reduction of maternal syphilis
incidence during pregnancy. Each of these parameters suggests
speciﬁc interventions that policymakers might choose to ap-
proach elimination goals. For example, test sensitivity may be
improved by new point-of-care syphilis tests [55], which may
also improve linkage between a positive test and receipt of
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penicillin treatment. The PMTCT services targeted before con-
ception may reduce the prevalence and incidence of syphilis
among women who may become pregnant, as well as their part-
ners. Such services might include, for example, expanding
counseling, testing, and treatment programs for syphilis in the
general population and for partners of pregnant women, as well
as counseling regarding behavioral risk reduction [56]. Identify-
ing and treating syphilis in women and their partners would
likely reduce transmission of the disease in addition to the prev-
alence. In addition, increasing uptake of third-trimester repeat
testing for syphilis ( per Brazilian MOH recommendations)
would be valuable to reduce the impact of incident maternal in-
fection on CS [48, 57]. It is noteworthy that CS projections were
partly limited by available Brazilian data. We used national in-
cidence estimates based on non-treponemal tests, and we down-
wardly adjusted these rates to account for both false-negative
results in the ﬁrst test and false-positive results in the second
test (Supplementary Appendix 1) [58].
Third, we identiﬁed the conditions necessary to achieve HIV
MTCT goals. On a national level, Brazil is currently meeting one
important goal for HIV elimination (projected rate of 0.29 HIV
cases/1000 LB, below the PAHO goal of≤0.30 cases/1000 LB) and
could signiﬁcantly surpass the goal with reasonable improvements
in HIV testing and treatment. This success reﬂects many years
of developing excellent infrastructure for HIV care [59], partic-
ularly in the areas of Brazil that were traditionally the epicenters
of the disease [8].However, Brazil is much further frommeeting
the second HIV-related goal, deﬁned as ≤2.0% MTCT, with a
projected current access MTCT risk of 7.1%. To reach the
≤2.0% MTCT goal, programs will need to support not only
increased testing and treatment (reﬂected in our ideal access
scenario; Figure 1) but also interventions to support adherence
throughout pregnancy (reﬂected in the “lowest transmission
risks”) [28, 29].
Fourth, the results for each of Brazil′s diverse regions high-
light the need to tailor HIV- and syphilis-related interventions
to speciﬁc contexts, both regionally and nationally. Considering
regional differences in CS, projected CS cases/1000 LB exceed
PAHO goals throughout all of Brazil’s regions (Figure 2), and
CS cases/1000 LB are highest in the North and Northeast.
These ﬁndings differ from Brazilian CS surveillance data,
which describe the highest CS rates in the Southeast region.
We hypothesize that these differences are due to a more robust
CS surveillance system in the Southeast compared with other
regions [11]. The higher CS incidence in the Northeast brings
the absolute number of CS cases on par with the Southeast
Figure 3. Three-way sensitivity analysis, showing impact of maternal syphilis prevalence, maternal syphilis incidence, and uptake prevention of mother-
to-child transmission (PMTCT) services. The vertical axis shows cases of congenital syphilis (CS)/1000 live births (LB). The horizontal axis shows the
prevalence of maternal syphilis in Brazil. The black arrow indicates the base case input of 0.2% incidence with a prevalence of 1.0%. Projected results
at base-case and “ideal” uptakes are shown. It is not possible to meet the Pan American Health Organization (PAHO) goals for elimination (deﬁned as ≤0.50
cases of CS/1000 LB) unless syphilis incidence drops to 0.0% and prevalence drops below 0.5% for current levels of uptake. If uptake increases to 95%,
incidence and prevalence still need to drop to at least 0.1% and 0.5%, respectively, to meet elimination targets. Transmission of syphilis still occurs at
“ideal access” rates due to remaining gaps in testing and treatment, 88% sensitivity of syphilis testing (Venereal Disease Research Laboratory), and imperfect
treatment efﬁcacy (97%). Although incidence and prevalence are varied independently in the ﬁgure, in reality they will increase or decrease together.
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despite a smaller population, underscoring the importance of
focusing resources on syphilis in the Northeast region.
Considering regional differences in HIV outcomes, it is note-
worthy that over half of annual infant infections with current
access in Brazil are projected to be in the South and Southeast
(420 of 790; Figure 2). This occurs despite relatively better ANC
services there than in other regions, due to both high HIV prev-
alence and the large population in these regions. However, the
North and Northeast regions have much higher projected HIV
MTCT risks, deﬁned as the risk of an HIV-infected woman
transmitting HIV to her infant, than the South and Southeast.
Combined with a stable or even increasing HIV prevalence in
those regions [60], this suggests that there is signiﬁcant poten-
tial to improve HIV outcomes in the North and Northeast as
well. Efforts to plan CS- and HIV-related programmatic modi-
ﬁcations throughout Latin America should incorporate the spe-
ciﬁc differences in disease prevalence and access to care between
settings, as exempliﬁed by the regions of Brazil, to ensure that
interventions have the greatest impact. The effectiveness of spe-
ciﬁc interventions toward these goals in each region is an im-
portant area of future implementation science investigation.
Model-based analyses have several limitations. Model out-
comes are based upon best available data at the time of analysis,
which were incomplete for several parameters. In some cases,
we made assumptions of the relationship between 2 events;
for example, the repeat tests were independent given the lack
of data on the false-negative and false-positive rate after a ﬁrst
false-negative or false-positive test. We conducted extensive
sensitivity analyses around key uncertain parameters, varying
them through wide plausible ranges, and our main conclusions
were unchanged except as noted (Supplementary Appendix 1).
In addition, models necessarily simplify complex biologic and
behavioral processes. For example, the behavior of pregnant
women’s partners is only indirectly addressed through the
issue of incident cases of syphilis in pregnancy [22, 23]. Despite
these limitations, model-based analysis can help estimate the
current status of PMTCT efforts and predict the measures nec-
essary to achieve elimination goals [16].
CONCLUSIONS
In conclusion, increasing access to ANC services to ideal levels
will have a substantial impact on vertical transmission of HIV
and syphilis, preventing lifelong disease among thousands of
newborns and reducing maternal morbidity and mortality
from HIV and syphilis. Interventions targeted to both diseases
can beneﬁt from the same infrastructure, personnel, and infor-
mation campaigns [61]. Achieving ideal access would result in
HIV transmission risks approaching regional goals, while syphilis
transmission rates would not reach these targets. In order to
achieve elimination, policies will need to address not only individ-
ual pregnant women, but also their partners and the nonpregnant
general population, to improve prevention through reduction of
disease prevalence and incidence.
Supplementary Material
Supplementary material is available online at Open Forum Infectious Diseas-
es (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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